The past and future of CD33 as therapeutic target in acute myeloid leukemia
- 1 July 2014
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 28 (4), 143-153
- https://doi.org/10.1016/j.blre.2014.04.001
Abstract
No abstract availableKeywords
This publication has 147 references indexed in Scilit:
- SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLBlood, 2013
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AMLBlood, 2012
- In VitroandIn VivoAntitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL againstAcute Myeloid LeukemiaAdvances in Hematology, 2012
- Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker moduleMolecular Immunology, 2011
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinBlood, 2011
- Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?Immunology, 2010
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Siglecs and their roles in the immune systemNature Reviews Immunology, 2007
- Clonal Development, Stem-Cell Differentiation, and Clinical Remissions in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1987